BVX vs. IMM, GENF, SNG, ROQ, BSFA, VAL, NSCI, IXI, OCTP, and EVG
Should you be buying BiVictriX Therapeutics stock or one of its competitors? The main competitors of BiVictriX Therapeutics include ImmuPharma (IMM), Genflow Biosciences (GENF), Synairgen (SNG), Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), ValiRx (VAL), NetScientific (NSCI), IXICO (IXI), Oxford Cannabinoid Technologies (OCTP), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
ImmuPharma (LON:IMM) and BiVictriX Therapeutics (LON:BVX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
ImmuPharma has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, BiVictriX Therapeutics has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500.
BiVictriX Therapeutics has lower revenue, but higher earnings than ImmuPharma. BiVictriX Therapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
ImmuPharma received 266 more outperform votes than BiVictriX Therapeutics when rated by MarketBeat users.
ImmuPharma's return on equity of -59.06% beat BiVictriX Therapeutics' return on equity.
21.1% of ImmuPharma shares are held by institutional investors. Comparatively, 34.8% of BiVictriX Therapeutics shares are held by institutional investors. 43.0% of ImmuPharma shares are held by insiders. Comparatively, 36.7% of BiVictriX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, BiVictriX Therapeutics' average media sentiment score of 0.68 beat ImmuPharma's score of 0.67 indicating that ImmuPharma is being referred to more favorably in the media.
Summary
ImmuPharma beats BiVictriX Therapeutics on 7 of the 11 factors compared between the two stocks.
Get BiVictriX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BiVictriX Therapeutics Competitors List
Related Companies and Tools
